Spots Global Cancer Trial Database for Nimotuzumab in Adults With Glioblastoma Multiforma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Nimotuzumab in Adults With Glioblastoma Multiforma

Official Title: Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV

Study ID: NCT00753246

Conditions

Adults With Glioblastoma Multiforma

Interventions

nimotuzumab

Study Description

Brief Summary: Determination of efficiency of nimotuzumab in adults with glioblastoma multiforma

Detailed Description: The objective of the present study is a comparison of treatment of patients with newly diagnosed glioblastoma multiforme grade IV. Patients will be randomized in one of two arms when included. Patients randomly assigned to arm A will receive Nimotuzumab (OSAG 101) plus Temozolomide concomitant with standard radiotherapy. Patients randomised in arm B will receive standard radiotherapy plus Temozolomide treatment.